| Today’s Big NewsMar 6, 2025 |
| By Gabrielle Masson A federal judge has blocked the Trump administration’s effort to slash National Institutes of Health grant payments amid ongoing litigation. |
|
|
|
By Gabrielle Masson President Donald Trump’s pick to lead the NIH, Jayanta Bhattacharya, M.D., Ph.D., said he will address recent cuts made to the agency if confirmed, but avoided sharing specific plans. |
By Nick Paul Taylor One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded (PDF) further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease. |
By Gabrielle Masson Under President Donald Trump’s administration, the Department of Government Efficiency has reportedly terminated leases for at least 748 federal sites, including 30 FDA facilities across 23 states. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
By Gabrielle Masson Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. |
By James Waldron ITM Isotope Technologies has provided more detail on how its lead radiotherapy bested the standard of care in a recent phase 3 study while revealing that the candidate was unable to prove a benefit in median overall survival. |
By James Waldron Denali Therapeutics’ amyotrophic lateral sclerosis drug has racked up another clinical miss this year, leaving the company to mull the asset’s future. |
By James Waldron Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. |
By James Waldron Zymeworks has pumped the brakes on plans to take one of its antibody-drug conjugates into the clinic so it can prioritize another candidate. |
By Kevin Dunleavy A federal district court in Texas will allow Novo Nordisk to intervene in a lawsuit pitting compounders against the FDA. The decision gives the Danish company a voice in the case which surrounds the validity of its claim that it can meet the skyrocketing demand for its semaglutide products. |
By Fraiser Kansteiner While the ebb and flow of mpox outbreaks may have taken a toll on Bavarian Nordic’s 2024 sales performance, the year also validated, in large part, the travel vaccines business the Danish company has been building out since the start of the decade. |
Fierce podcasts Don’t miss an episode |
| Digital health venture capital funding cooled off in 2024 following the fever pitch of investment from 2020 to 2022. But investors still see bright opportunities for the sector. |
|
|---|
|
|
|
Thursday, March 20, 2025 | 11am ET / 8am PT AI is no longer a novelty—it's an expectation. As stakeholders demand evidence of real-world impact, the focus is shifting from the tools themselves to the tangible results they deliver. Join us to explore how predictive sales intelligence and omnichannel strategies are transforming HCP engagement. Register now. 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
